Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...

Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by ...

Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by ...

Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year outcomes of the Evolut transfemoral transcatheter aortic valve replacement ...

1,414 patients were randomized, with 730 receiving TAVR with either a Medtronic Evolut R, PRO, or CoreValve™ and 684 undergoing surgery. "Results at five years support Evolut's supra-annular ...